Stroke survivors with uncontrolled high blood pressure who added the inexpensive diuretic spironolactone to their treatment achieved significantly lower blood pressure and were nearly twice as likely to reach recommended targets compared with those receiving usual care, according to preliminary late-breaking research presented at the American Heart Association's Scientific Sessions 2026 in Chicago.
The findings matter because High blood pressure is the leading controllable risk factor for a recurrent stroke, yet many survivors struggle to reach recommended targets. Nearly one in four stroke survivors will have another stroke, and having more than one stroke increases the risk of severe disability and poorer quality of life. Up to 80% of strokes are preventable, and lowering blood pressure is the most important step in prevention, according to the 2021 American Heart Association/American Stroke Association Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack.
In the REDUCE trial, 160 adult stroke survivors with uncontrolled high blood pressure were randomized to receive daily spironolactone or usual post-stroke care. At three months, those taking spironolactone had home systolic blood pressure about 8 mm Hg lower on average (126 mm Hg vs. 133 mm Hg) and diastolic blood pressure about 4 mm Hg lower. Additionally, 52% of the spironolactone group reached the recommended goal of less than 130/80 mm Hg, compared with 30% of the usual care group. The benefit persisted at six months, with systolic blood pressure about 7 mm Hg lower in the spironolactone group.
Spironolactone is a long-available, low-cost diuretic that blocks aldosterone, a hormone that signals the kidneys to retain salt and water. It is typically the fourth medication added for high blood pressure, but the trial's exploratory analysis suggested that starting it sooner—within three months of a stroke—may produce larger blood pressure reductions. The medication was well tolerated, with serious side effects requiring hospitalization occurring at similar rates (15% vs. 16%), and high potassium levels in about 4% of participants without life-threatening issues. The trial included both ischemic stroke and intracerebral hemorrhage survivors.
"We were surprised to see that blood pressure dropped twice as much as we expected," said co-lead author Jordana B. Cohen, M.D., M.S.C.E., FAHA. "We hope these findings encourage healthcare professionals to consider adding spironolactone sooner." The results underscore the importance of routine home blood pressure monitoring, especially given the cardiovascular risks associated with any level of high blood pressure. As noted in the abstract, the study was not designed to determine whether spironolactone reduces the risk of another stroke or heart attack, and larger, longer trials are needed. The findings are considered preliminary until published in a peer-reviewed journal. The study was funded by a Bugher Center grant from the American Heart Association, and additional resources are available in the 2026 Online Program Planner.


